Brokerage Firm Rating on Bruker Corporation (BRKR)

Bruker Corporation (BRKR) : The consensus on Bruker Corporation (BRKR) based on 10 analyst recommendation on the company stock is 2.3, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 5 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst also believes that the downside risk to the stock is higher and suggests a Sell on Bruker Corporation (BRKR).

Bruker Corporation (BRKR) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $30 and the lowest price target forecast is $23. The average forecast of all the analysts is $26.63 and the expected standard deviation is $2.92.


Company shares have received an average consensus rating of Hold for the current week Bruker Corporation (NASDAQ:BRKR): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $22.24 and $22.11 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $22.45. The buying momentum continued till the end and the stock did not give up its gains. It closed at $22.33, notching a gain of 1.04% for the day. The total traded volume was 784,295 . The stock had closed at $22.10 on the previous day.

In a related news, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Bruker Corp, Laukien Frank H had purchased shares worth of $99,967 in a transaction dated on June 14, 2016. A total of 4,174 shares were purchased at a price of $23.95 per share. The information is based on open market trades at the market prices.Option exercises are not covered.

Bruker Corporation is a designer and manufacturer of life science and materials research systems and associated products that address the needs of a range of customers in life science research, pharmaceuticals, applied markets, nanotechnology, cell biology, clinical research, microbiology and in-vitro diagnostics. The Company operates through two segments: Bruker Scientific Instruments (BSI) and Bruker Energy & Supercon Technologies (BEST). BSI is organized into three operating segments: the Bruker BioSpin Group, the Bruker CALID Group and the Bruker Nano Group. BEST designs, manufactures and distributes superconducting materials. The company maintains technical and manufacturing centers in Europe and North America, and it has sales offices located throughout the world.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.